Treatment of Dry Eye Disease - Comprehensive Guide

Overview and Treatment Philosophy

1. Control of symptoms
2. Prevention of ocular surface damage
3. Breaking the self-perpetuating cycle of inflammation

TFOS DEWS Stepwise Management Framework

LEVEL 1 - First-Line Measures (Mild Disease)

• Establish realistic expectations - explain that DED is usually chronic and manageable, not curable
• Blink training: Patients should be taught to blink consciously and completely while reading, watching TV, or using screens
• Screen positioning: Computer monitors should be placed below eye level to minimize palpebral aperture width and reduce evaporation
• Contact lens wear: Review lens material, replacement schedule, and wearing hours; consider switching to silicone hydrogel or reducing wear time
• Environmental modification: Increase indoor humidity using humidifiers, avoid direct airflow from fans/air conditioning, wear wraparound glasses outdoors
• Laser refractive surgery caution: Warn patients that LASIK can exacerbate or unmask pre-existing DED (corneal nerve disruption reduces reflex tearing)
• Reduce screen time or use the 20-20-20 rule

• Antihistamines (H1 blockers)
• Tricyclic antidepressants and SSRIs
• Beta-blockers (systemic and topical)
• Diuretics
• Isotretinoin
• Antipsychotics
• Anticholinergics (e.g., oxybutynin, scopolamine)
• Hormone replacement therapy (estrogen-only)
• Any topical preserved ophthalmic medication taken long-term

• The optimal frequency of instillation varies with agent and disease severity
• No single preparation has demonstrated superiority; patient preference often guides selection
• Preservative-free (PF) formulations should be used for any patient requiring drops more than 3-4 times/day - benzalkonium chloride (BAK) is toxic to goblet cells and the epithelium

• Warm compresses: Soften inspissated meibomian secretions; 5-10 min twice daily. A face cloth or commercial eyelid warming mask works
• Lid scrubs: Eyelid detergent (diluted baby shampoo 1:1 with water, or commercial lid wipes) to remove debris, crusts, and biofilm
• Some ophthalmologists avoid scrubs as they can irritate
• Reparative lid surgery (early consideration): Entropion, ectropion, lid laxity, or scleral show should be corrected promptly as they cause mechanical surface damage

• Tape lids closed at bedtime
• Swim goggles during sleep
• In extreme cases: lateral tarsorrhaphy

LEVEL 2 - Second-Line Measures (Mild-Moderate Disease)

• Short courses (1-2 weeks) of low-potency steroids (loteprednol, fluorometholone) reduce acute surface inflammation and can "prime" the eye before starting cyclosporine
• Not for long-term use due to risks of IOP elevation, cataract, and infection
• Useful in flares of inflammatory DED

• Restasis (0.05%) - FDA-approved for keratoconjunctivitis sicca (KCS)
• Mechanism: calcineurin inhibitor - blocks T-lymphocyte activation, reduces IL-2-driven inflammatory cascade on the ocular surface, restoring goblet cell density
• Clinical trials showed statistically significant improvement in tear production (Schirmer I test) and symptoms
• Onset of action: typically 3-6 months
• Side effect: burning/stinging on instillation (common; limits tolerability)
• Cequa (cyclosporine 0.09%) - nanomicellular aqueous formulation; FDA-approved with improved bioavailability and lower instillation site pain compared to Restasis
• Dosing: twice daily, both eyes

• FDA-approved for DED signs and symptoms
• Mechanism: LFA-1 (lymphocyte function-associated antigen-1) antagonist - blocks the LFA-1/ICAM-1 interaction, disrupting T-cell recruitment and activation on the ocular surface
• Improves symptoms vs. placebo in RCTs; not directly compared with cyclosporine in head-to-head trials
• Side effects: ocular irritation, dysgeusia (unusual taste sensation due to nasolacrimal drainage)
• Dosing: twice daily; works faster than cyclosporine (some benefit within 2-12 weeks)

• Omega-3 fatty acids (EPA/DHA from fish oil) have anti-inflammatory properties
• May improve meibomian gland function and tear stability in MGD-driven evaporative DED
• Evidence is mixed (DREAM trial showed no significant benefit vs. olive oil placebo), but widely used
• Omega-6 (gamma-linolenic acid from evening primrose or borage oil) may also be beneficial

• Doxycycline (100 mg/day or 50 mg twice daily) is the preferred agent
• Mechanism: not purely antimicrobial - key effect is inhibition of matrix metalloproteinases (MMPs), which degrade tear film proteins and damage the epithelium; also reduces bacterial lipase activity, improving meibum quality; anti-inflammatory via NF-κB pathway inhibition
• Minocycline is an alternative
• Low-dose (sub-antimicrobial) doxycycline 40 mg/day (Oracea) is also effective with lower antibiotic resistance risk
• Duration: typically 3-6 months

• Preserve natural tears by blocking nasolacrimal drainage
• Indicated when symptoms persist despite regular artificial tear use
• 90% of tears drain through the inferior punctae - plugs are therefore inserted in the two inferior punctae first
• Trial with temporary/dissolvable collagen plugs first before permanent occlusion (to ensure epiphora doesn't occur)
• Silicone intracanalicular or punctal plugs for longer-term use
• Most frequent complication: excessive tearing (epiphora)

• Pilocarpine 5 mg 3-4x/day - M3 muscarinic agonist; stimulates lacrimal and salivary gland secretion; evidence from RCTs for both dry eye and dry mouth (especially in Sjögren's)
• Cevimeline - more selective M3/M1 agonist; longer duration than pilocarpine; 30 mg 3x/day
• Rebamipide - mucin secretagogue; stimulates goblet cell mucin production; widely used in Asia
• Varenicline nasal spray (Tyrvaya) - FDA-approved; activates the trigeminal parasympathetic pathway via the nose to stimulate tear production; novel delivery route; 0.03 mg twice daily
• Side effects of muscarinic agonists: sweating, flushing, urinary frequency, GI cramping, bradycardia - use with caution in asthma, cardiac disease, peptic ulcer

• Wraparound frames with side shields or sealed chambers reduce air exposure and evaporation
• Useful in severe evaporative DED and in occupational exposure to dry environments

LEVEL 3 - Third-Line Measures (Moderate-Severe Disease)

• Blood drawn from the patient, processed in a specialty laboratory
• Typically diluted to 20% concentration in saline
• Contains growth factors (EGF, TGF-β, fibronectin), vitamins (A, B12, C), IgA antibodies, antioxidants, and proteins absent from artificial tears
• Particularly effective in severe KCS, Sjögren syndrome, graft-versus-host disease (GVHD)-related DED, post-LASIK persistent epithelial defects, and recurrent erosions
• Requires refrigeration; limited shelf-life; preparation is resource-intensive
• Umbilical cord serum (allogeneic) is an alternative with potentially higher growth factor concentrations; avoids patient phlebotomy; emerging evidence

• Scleral lenses: Large-diameter rigid gas-permeable lenses that vault the cornea entirely and rest on the scleral conjunctiva; reservoir of saline solution bathes the cornea continuously - highly effective in severe DED, irregular corneas, and Stevens-Johnson syndrome
• Bandage soft contact lenses: Protect the epithelium, reduce pain from erosions; used short-term in severe surface disease
• Both require careful fitting and compliance with hygiene

• Indicated when temporary plugs have proven beneficial without causing epiphora
• Methods:
  • Silicone plugs (removable but sometimes poorly tolerated - can extrude or migrate)
  • Thermal cautery (punctal cauterization) - outpatient procedure
  • Laser cauterization
  • Surgical occlusion (ligation)
• Permanent occlusion is particularly appropriate in patients with severe aqueous deficiency

LEVEL 4 - Fourth-Line Measures (Severe/Refractory Disease)

• Indicated in severe DED associated with systemic autoimmune conditions (Sjögren syndrome, RA, SLE, GVHD)
• Hydroxychloroquine (often first-line for Sjögren's systemic features)
• Methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide - used by rheumatologists for severe extraglandular disease
• Rituximab (anti-CD20) - evidence in Sjögren's, particularly for reducing B-cell-driven salivary/lacrimal inflammation
• Short systemic corticosteroid courses for acute severe flares

• Tarsorrhaphy (lateral or medial): Partial permanent closure of the eyelid to reduce ocular surface exposure; used in severe neurotrophic keratopathy, facial palsy, or refractory severe DED
• Botulinum toxin injection to the orbicularis muscle: Controls the blepharospasm that often accompanies severe DED; injected at the medial canthus it can also reduce tear drainage

• Amniotic membrane transplantation: Provides anti-inflammatory, anti-scarring, and pro-epithelialization effects; used in acute severe surface disease and persistent epithelial defects
• Mucous membrane grafting: Autologous oral mucosa transplanted to reconstruct the conjunctival fornix in severe cicatricial disease (Stevens-Johnson, ocular pemphigoid)
• Salivary gland autotransplantation: Submandibular gland transposition to the orbit - the saliva acts as a tear substitute; reserved for end-stage bilateral severe DED with no other options; risk of mucus hypersecretion and stone formation

Disease-Specific Treatment Considerations

Evaporative Dry Eye (MGD-Dominant)

• First focus on lid hygiene (warm compresses, lid scrubs)
• Thermal pulsation devices (LipiFlow): In-office device that applies controlled heat from inside the eyelid + massage to express stagnant meibomian secretions; single treatment provides months of benefit
• Intense Pulsed Light (IPL): Used periocularly; reduces telangiectatic lid vessels, decreases inflammatory mediators reaching the meibomian glands; FDA-cleared for MGD
• Meibomian gland probing: Mechanical dilation of stenosed gland orifices
• Tetracyclines, eyelid sprays, omega-3 supplements
• Topical azithromycin (macrolide anti-inflammatory + antimicrobial on lid margin)

Aqueous-Deficient Dry Eye (Sjögren's Syndrome)

• Cyclosporine/lifitegrast for inflammation
• Pilocarpine/cevimeline to stimulate residual secretion
• Punctal occlusion to conserve tears
• Autologous serum drops in severe cases
• Address systemic disease with rheumatology

Fig. Treatment algorithm for primary Sjögren's syndrome - Firestein & Kelley's Textbook of Rheumatology

GVHD-Related Dry Eye

• Often severe and bilateral
• Autologous or umbilical cord serum drops are particularly effective
• Scleral lenses
• Topical tacrolimus or cyclosporine
• Systemic immunosuppression (managed by transplant team)

Neurotrophic Keratopathy (Reduced Corneal Sensation)

• Cenegermin (Oxervate) - recombinant human nerve growth factor (rhNGF) eye drops; FDA-approved; promotes corneal re-innervation and healing
• Preservative-free artificial tears
• Scleral lenses
• Tarsorrhaphy if severe

Drug-Induced / Iatrogenic Dry Eye

• Post-LASIK: usually self-limited 6-12 months; treat with preservative-free drops ± autologous serum if persistent
• BAK toxicity: switch all drops to preservative-free formulations
• Isotretinoin: dose reduction or cessation if tolerated clinically; supplemental lubrication

Emerging and Investigational Therapies

• Topical insulin eye drops: Systematic reviews (2025) show promise for persistent epithelial defects and neurotrophic disease
• Extracellular vesicles (exosomes): Early evidence for anti-inflammatory and regenerative properties in DED and Sjögren's (2025 systematic review)
• Blood component therapy (platelet-rich plasma, plasma-derived drops): Network meta-analysis (2024) supports their use in severe DED
• Tanezumab and other anti-NGF: For neuropathic ocular pain component
• SYL1001 (siRNA against TRPV1): Reducing pain hypersensitivity
• Stem cell-derived tear substitutes

Mucolytic Therapy

• Useful specifically for patients with corneal filaments and mucous plaques, which the drug dissolves
• May cause stinging; has limited shelf-life and is malodorous
• Manual debridement of filaments is an alternative/adjunct

Preservative Management - Key Points

• Benzalkonium chloride (BAK): The most common preservative; toxic to goblet cells and epithelium with repeated exposure; prolongs surface exposure time but damages surface cells
• Polyquad and Purite: Newer preservatives with significantly lower ocular surface toxicity - preferred when preservative-free is unavailable
• Rule: Preservative-free drops should be used when instilling drops more than 3-4 times daily, in any moderate-severe disease, and in all patients with concurrent topical glaucoma therapy

Summary Table: Treatment by Severity

Monitoring Response to Treatment

• Tear osmolarity (TearLab): correlates with treatment effectiveness in long-term follow-up; target <308 mOsm/L; inter-eye difference >8 mOsm/L suggests instability
• Schirmer test: improvement in strip wetting after cyclosporine therapy
• Corneal/conjunctival staining (fluorescein, lissamine green): reduction in staining area
• Symptom scores: OSDI (Ocular Surface Disease Index), SPEED questionnaire
• Tear meniscus height on slit-lamp or OCT

• Kanski's Clinical Ophthalmology: A Systematic Approach, 10th Ed., pp. 179-183
• Goodman & Gilman's The Pharmacological Basis of Therapeutics, pp. 1489-1490
• Firestein & Kelley's Textbook of Rheumatology, pp. 1573-1578
• TFOS DEWS III Management and Therapy Report (2025) - review article
• Blood component therapy meta-analysis PMID 39736981 (2024)
• Topical pharmacologic treatments systematic review PMID 40749992 (2025, Ocular Surface)